All Stories

  1. Changes in Adaptive Immunity in Autoimmune Diseases and Aging: Shared Features, Key Differences, and Implications for Immune Vulnerability
  2. Assessing Peripheral Blood Biomarkers and Predictive Patterns in Multiple Sclerosis Using Cytokines and Immune Gene Expression Profiles in Ocrelizumab-Treated Patients: Tracking Tumor Necrosis Factor
  3. Multiple low dose streptozotocin‐induced diabetes as a model for studying autoimmune diabetes in humans
  4. Vaccine-Induced Humoral and Cellular Response to SARS-CoV-2 in Multiple Sclerosis Patients on Ocrelizumab
  5. Immunomodulatory effects of HYCO-3, a dual action CO-releaser/Nrf2 activator
  6. Anti-Neuroinflammatory Effects of a Novel Bile Acid Derivative
  7. NRF2 Plays a Crucial Role in the Tolerogenic Effect of Ethyl Pyruvate on Dendritic Cells
  8. Brain inflammation in experimental autoimmune encephalomyelitis induced in Dark Agouti rats with spinal cord homogenate
  9. ILC3: a case of conflicted identity
  10. Phenethyl Ester of Gallic Acid Ameliorates Experimental Autoimmune Encephalomyelitis
  11. Phenethyl ester of rosmarinic acid ameliorates experimental autoimmune encephalomyelitis
  12. Ethyl pyruvate, a versatile protector in inflammation and autoimmunity
  13. Ethyl Pyruvate Ameliorates Experimental Autoimmune Myocarditis
  14. Sepsis and multiple sclerosis: Causative links and outcomes
  15. Benfotiamine Reduces Dendritic Cell Inflammatory Potency
  16. Upregulation of Tolerogenic Pathways by the Hydrogen Sulfide Donor GYY4137 and Impaired Expression of H2S-Producing Enzymes in Multiple Sclerosis
  17. MIF and insulin: Lifetime companions from common genesis to common pathogenesis
  18. Comparison of dendritic cells obtained from autoimmunty-prone and resistant rats
  19. Oral neonatal antibiotic treatment perturbs gut microbiota and aggravates central nervous system autoimmunity in Dark Agouti rats
  20. The H2S Donor GYY4137 Stimulates Reactive Oxygen Species Generation in BV2 Cells While Suppressing the Secretion of TNF and Nitric Oxide
  21. Anti-encephalitogenic effects of ethyl pyruvate are reflected in the central nervous system and the gut
  22. Anti-encephalitogenic effects of cucumber leaf extract
  23. Strain-specific helper T cell profile in the gut-associated lymphoid tissue
  24. Pomegranate peel extract ameliorates autoimmunity in animal models of multiple sclerosis and type 1 diabetes
  25. Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis
  26. Correlation of Gut Microbiota Composition with Resistance to Experimental Autoimmune Encephalomyelitis in Rats
  27. Cucurbitacin E Potently Modulates the Activity of Encephalitogenic Cells
  28. Gut-associated lymphoid tissue, gut microbes and susceptibility to experimental autoimmune encephalomyelitis
  29. The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K
  30. Cell death of spinal cord ED1 + cells in a rat model of multiple sclerosis
  31. Micro RNA-155 participates in re-activation of encephalitogenic T cells
  32. Tumor necrosis factor stimulates expression of CXCL12 in astrocytes
  33. Short term exposure to ethyl pyruvate has long term anti-inflammatory effects on microglial cells
  34. Activity, but not mRNA expression of gelatinases correlates with susceptibility to experimental autoimmune encephalomyelitis
  35. A Comparative Analysis of Multiple Sclerosis-Relevant Anti-Inflammatory Properties of Ethyl Pyruvate and Dimethyl Fumarate
  36. Effect of ethyl pyruvate on central nervous system inflammation
  37. Saquinavir-NO Inhibits IL-6 Production in Macrophages
  38. Study of the anticancer properties of methyl- and phenyl-substituted carbon- and silicon-bridged ansa-titanocene complexes
  39. Anticancer Potential of (Pentamethylcyclopentadienyl)chloridoiridium(III) Complexes Bearing κPand κP,κS-Coordinated Ph2PCH2CH2CH2S(O)xPh (x=0-2) Ligands
  40. Synthesis, X-ray structure and strong in vitro cytotoxicity of novel organoruthenium complexes
  41. Multiple Sclerosis: Molecular Mechanisms and Therapeutic Opportunities
  42. Regional cytokine responses to pulmonary aspergillosis in immunocompetent rats
  43. Biological activity of neutral and cationic iridium(III) complexes with κP and κP,κS coordinated Ph2PCH2S(O)xPh (x = 0–2) ligands
  44. The Frequency of Allele CCR5∆32 in a Serbian Population / UČESTALOST ALELA CCR5∆32 U SRPSKOJ POPULACIJI
  45. No-Modified Saquinavir is Equally Efficient Against Doxorubicin Sensitive and Resistant Non-Small Cell Lung Carcinoma Cells / MODIFIKOVANA KOVANA FORMA SAKVINAVIRA EFIKASNO SU PRIMI RA RAST ĆELIJA NESITNOĆELIJSKOG KARCINOMA PLUĆA RAZLIČITE OSETUIVOSTI ...
  46. High interleukin-10 expression within the central nervous system may be important for initiation of recovery of Dark Agouti rats from experimental autoimmune encephalomyelitis
  47. Apotransferrin inhibits interleukin-2 expression and protects mice from experimental autoimmune encephalomyelitis
  48. Nitric oxide inhibits CXCL12 expression in neuroinflammation
  49. CXCL12-γ expression is inhibited in neuroinflammation
  50. Saquinavir-NO inhibits S6 kinase activity, impairs secretion of the encephalytogenic cytokines interleukin-17 and interferon-gamma and ameliorates experimental autoimmune encephalomyelitis
  51. The elimination of P-glycoprotein over-expressing cancer cells by antimicrobial cationic peptide NK-2: The unique way of multi-drug resistance modulation
  52. Betulinic acid regulates generation of neuroinflammatory mediators responsible for tissue destruction in multiple sclerosis in vitro
  53. Antitumor potential of novel betulin derivative on human A375 melanoma cell line
  54. Tenascins and inflammation in disorders of the nervous system
  55. Cell-type dependent response of melanoma cells to aloe emodin
  56. Therapeutic Potential of Nitric Oxide-Modified Drugs in Colon Cancer Cells
  57. CXCL12: Role in neuroinflammation
  58. Effects of subacute oral warfarin administration on peripheral blood granulocytes in rats
  59. Novel methylene modified cyclohexyl ethylenediamine-N,N′-diacetate ligands and their platinum(IV) complexes. Influence on biological activity
  60. Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL
  61. CXCL12 in control of neuroinflammation
  62. Platinum(ii/iv) complexes containing ethylenediamine-N,N′-di-2/3-propionate ester ligands induced caspase-dependent apoptosis in cisplatin-resistant colon cancer cells
  63. Melanoma tumor inhibition by tetrachlorido(O,O′-dibutyl-ethylenediamine-N,N′-di-3-propionate)platinum(iv) complex: in vitro and in vivo investigations
  64. Novel octahedral Pt(IV) complex with di-n-propyl-(S,S)-ethylenediamine-N,N′-di-2-(3-cyclohexyl)propanoato ligand exerts potent immunomodulatory effects
  65. CXCL12 expression within the CNS contributes to the resistance against experimental autoimmune encephalomyelitis in Albino Oxford rats
  66. Contact allergic response to dinitrochlorobenzene (DNCB) in rats: Insight from sensitization phase
  67. It is still not for the old iron: adjuvant effects of carbonyl iron in experimental autoimmune encephalomyelitis induction
  68. Cytotoxic and immune-sensitizing properties of nitric oxide-modified saquinavir in iNOS-positive human melanoma cells
  69. Astrocytes in the tempest of multiple sclerosis
  70. In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells
  71. Dry olive leaf extract (DOLE) down-regulates the progression of experimental immune-mediated diabetes by modulation of cytokine profile in the draining lymph nodes
  72. Multiple antimelanoma potential of dry olive leaf extract
  73. Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO
  74. Dried leaf extract of Olea europaea ameliorates islet-directed autoimmunity in mice
  75. Strain difference in susceptibility to experimental autoimmune encephalomyelitis in rats correlates with TH1 and TH17-inducing cytokine profiles
  76. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions
  77. The novel NO-donating compound GIT-27NO inhibits in vivo growth of human prostate cancer cells and prevents murine immunoinflammatory hepatitis
  78. Dry olive leaf extract ameliorates experimental autoimmune encephalomyelitis
  79. The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt
  80. Transforming Growth Factor-β1 in Balkan Endemic Nephropathy
  81. T cells cooperate with palmitic acid in induction of beta cell apoptosis
  82. Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells
  83. Methylprednisolone inhibits IFN-γ and IL-17 expression and production by cells infiltrating central nervous system in experimental autoimmune encephalomyelitis
  84. Murine brain endothelial cells differently modulate interferon-γ and interleukin-17 production in vitro
  85. Kinetics of IFN-γ and IL-17 expression and production in active experimental autoimmune encephalomyelitis in Dark Agouti rats
  86. Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid–nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells
  87. Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo
  88. Methylprednisolone inhibits interleukin-17 and interferon-gamma expression by both naive and primed T cells
  89. Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus
  90. In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models
  91. Astrocytes stimulate interleukin-17 and interferon-γ production in vitro
  92. B9. Tumoricidal activity of GIT-27NO depends on RNS and ROS generation
  93. C20. Novel NO-donation compound GIT-27NO possesses strong tumoricidal capacity in vitro and in vivo
  94. A Potent Immunomodulatory Compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxasole Acetic Acid, Prevents Spontaneous and Accelerated Forms of Autoimmune Diabetes in NOD Mice and Inhibits the Immunoinflammatory Diabetes Induced by Multiple Low Doses of Streptoz...
  95. Acidosis affects tumor cell survival through modulation of nitric oxide release
  96. Strain difference in susceptibility to experimental autoimmune encephalomyelitis between Albino Oxford and Dark Agouti rats correlates with disparity in production of IL-17, but not nitric oxide
  97. Interleukin-17 stimulates inducible nitric oxide synthase-dependent toxicity in mouse beta cells
  98. Critical Role of Macrophage Migration Inhibitory Factor Activity in Experimental Autoimmune Diabetes
  99. [Pt(HPxSC)Cl3], a novel platinum(IV) compound with anticancer properties
  100. The Mechanisms of 6-Hydroxydopamine-Induced Astrocyte Death
  101. Aloe emodin decreases the ERK-dependent anticancer activity of cisplatin
  102. Iron protects astrocytes from 6-hydroxydopamine toxicity
  103. Anti-glioma action of aloe emodin: the role of ERK inhibition
  104. Novel platinum(IV) complexes induce rapid tumor cell deathin vitro
  105. Novel ruthenium complex K2[Ru(dmgly)Cl4]·2H2O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes
  106. Iron down-regulates macrophage anti-tumour activity by blocking nitric oxide production
  107. Immunosuppressive and anti-inflammatory action of antioxidants in rat autoimmune diabetes
  108. Taxol activates inducible nitric oxide synthase in rat astrocytes: the role of MAP kinases and NF-?B
  109. Inducible nitric oxide synthase activation by interleukin-17
  110. 5-Aza-2′-deoxycytidine and paclitaxel inhibit inducible nitric oxide synthase activation in fibrosarcoma cells
  111. 5-Aza-2′-deoxycytidine stimulates inducible nitric oxide synthase induction in C6 astrocytoma cells
  112. Astrocyte-induced regulatory T cells mitigate CNS autoimmunity
  113. Mycophenolic acid inhibits activation of inducible nitric oxide synthase in rodent fibroblasts
  114. The role of interleukin-17 in inducible nitric oxide synthase-mediated nitric oxide production in endothelial cells
  115. Decreased Frequency of the Tumor Necrosis Factor α –308 Allele in Serbian Patients with Multiple Sclerosis
  116. Inhibition of autoimmune diabetes by mycophenolate mofetil is associated with down-regulation of TH1 cytokine-induced apoptosis in the target tissue
  117. IMMUNOSUPPRESSANTS LEFLUNOMIDE AND MYCOPHENOLIC ACID INHIBIT FIBROBLAST IL-6 PRODUCTION BY DISTINCT MECHANISMS
  118. Down-regulation of multiple low dose streptozotocin-induced diabetes by mycophenolate mofetil
  119. Mycophenolic acid downregulates inducible nitric oxide synthase induction in astrocytes
  120. Nitric oxide metabolites and interleukin-6 in cerebrospinal fluid from multiple sclerosis patients
  121. Necrotic tumor cells oppositely affect nitric oxide production in tumor cell lines and macrophages
  122. Interleukin-17 stimulates inducible nitric oxide synthase activation in rodent astrocytes
  123. Uric acid levels in sera from patients with multiple sclerosis
  124. Amphotericin B potentiates the activation of inducible nitric oxide synthase and causes nitric oxide-dependent mitochondrial dysfunction in cytokine-treated rodent astrocytes
  125. Leflunomide inhibits activation of inducible nitric oxide synthase in rat astrocytes